Background
==========

Approximately 15% of couples suffer from infertility, and it is estimated that male infertility is the cause in 50% of cases \[[@b1-medscimonit-25-4423]\]. Male infertility can be attributed to several factors such as the obstruction or absence of seminal pathways, varicocele, endocrinological disorders, cryptorchidism, and infections \[[@b2-medscimonit-25-4423]\]. Genetic alterations are another cause of male infertility, especially in patients with NOA. NOA caused by a genetic factor lacks effective treatment, but a clear diagnosis would play an important role in genetic counseling for patients experiencing difficulties in selecting an appropriate fertility treatment.

Genetic defects commonly observed in infertile males include karyotypic abnormalities (such as 47,XXY) and microdeletions of the Y chromosome, although the majority of cases remain idiopathic \[[@b3-medscimonit-25-4423]\]. In recent years, the relationship between single nucleotide polymorphisms (SNPs) and male infertility has received increasing attention \[[@b4-medscimonit-25-4423]--[@b6-medscimonit-25-4423]\]. We previously carried out high-throughput DNA sequencing of 4 SNPs (rs4331, rs4316, rs4343, and rs4362) in the angiotensin-converting enzyme gene (ACE). This revealed that particular genotypes of the 4 SNPs led to changes in the levels of reproductive hormones or seminal plasma biochemical markers in a case--control cohort from Northeast China \[[@b7-medscimonit-25-4423]\].

ACE is a key enzyme in the renin--angiotensin system (RAS) that converts angiotensin I to angiotensin II. ACE has 2 isoforms: somatic ACE (sACE) and testis-specific ACE (tACE) \[[@b8-medscimonit-25-4423],[@b9-medscimonit-25-4423]\]. ACE SNPs have been associated with the risk of preeclampsia in pregnant women \[[@b10-medscimonit-25-4423]\], hypertrophic cardiomyopathy \[[@b11-medscimonit-25-4423]\], and migraine \[[@b12-medscimonit-25-4423]\]. Moreover, the activity of tACE was also associated with infertility in some studies. Animals lacking ACE further suggest a role for the enzyme in male fertility \[[@b13-medscimonit-25-4423],[@b14-medscimonit-25-4423]\], and this is supported by the analysis of human samples \[[@b15-medscimonit-25-4423],[@b16-medscimonit-25-4423]\]. Additionally, Zalata et al. \[[@b17-medscimonit-25-4423]\] reported that ACE deletion is associated with abnormal seminal variables. However, Liao et al. \[[@b18-medscimonit-25-4423]\] showed that ACE polymorphisms were unlikely to contribute to the pathogenesis of male infertility in the Singapore population.

Therefore, in this study, we further explored whether ACE SNPs rs4316, rs4331, rs4343, and rs4362 were associated with NOA Chinese Han patients from Northeast China.

Material and Methods
====================

Subjects
--------

A total of 121 infertile men were collected from the Center for Reproductive Medicine of First Hospital, Jilin University, China between January 2013 and February 2016. Patients were diagnosed with NOA by semen analysis and testicular fine needle aspiration cytology. A total of 256 control subjects were randomly selected from sperm donors at the Human Sperm Bank of Jilin Province between October 2014 and November 2015. Peripheral blood G-banding karyotype analysis and Y chromosome AZF microdeletion detection were carried out for all cases, and those with chromosomal abnormalities or AZF microdeletions were excluded. All patients and controls were of Han ethnicity and were from Northeast China. This study was approved by the Ethics Committee of the First Hospital of Jilin University, and all participants provided their written informed consent for participation.

Semen analysis
--------------

Samples were obtained as previously described \[[@b19-medscimonit-25-4423]\]. Semen analysis was performed according to the WHO Laboratory Manual for the Examination and Processing of Human Semen (2010) with the following cutoff points for healthy semen: normal sperm morphology 4%, semen volume 1.5 ml, total sperm count 39×10^6^/eja, sperm concentration 15×10^6^/ml, and sperm total motility 40%.

Evaluation of biochemical markers
---------------------------------

Semen samples were centrifuged at 3,000×g for 15 min to remove spermatozoa and were frozen at −20°C until analysis. The total fructose concentration and neutral alpha-glucosidase in the seminal plasma were evaluated by seminal plasma fructose quantitative assay kit (Indole method) and seminal plasma neutral alpha-glucosidase quantitative assay kit (Enzyme method), respectively (Shenzhen Huakang Co., Ltd., Shenzhen, China). The seminal plasma zinc concentration was measured by seminal plasma zinc quantitative assay kit (modified 5-Br-PAPS) (Shenzhen Huakang Co., Ltd.).

Serum reproductive hormone analysis
-----------------------------------

The levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E~2~), prolactin (PRL), and inhibin B(INHB) were measured by electrochemiluminescence immunoassays using the Elecsys 2010 Chemistry Analyzer (Roche, Mannheim, Germany), based on the manufacturer's instructions.

SNP selection and genotyping
----------------------------

Genotyping was performed by Shanghai BioWing Applied Biotechnology Co., Ltd. (Shanghai, China) using LDR--PCR \[[@b20-medscimonit-25-4423]\]. Genomic DNA was extracted from ethylenediaminetetraacetic acid-anticoagulated blood using standard protocols. Target DNA sequences were amplified in a multiplex PCR method using primers shown in [Table 1](#t1-medscimonit-25-4423){ref-type="table"}. PCR was conducted in a 20 μl reaction mixture containing 1 × buffer, 50 ng of genomic DNA, 0.6 μl Mg^2+^ (3.0 mmol/l), 2 μl of deoxynucleotide triphosphates (2.0 mmol/l), 2.0 μl of primer mix, 0.3 μl of 1U Taq Polymerase (Shanghai BioWing Applied Biotechnology Co., Ltd), and 12.2 μl of ddH~2~O. The reaction was run in a Gene Amp PCR System 9600 thermal cycler (Perkin-Elmer, Norwalk, CT, USA) as follows: primary denaturation at 95°C for 2 min, then 40 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 90 s, and extension at 65°C for 30 s, followed by an extra extension at 65°C for 10 min. Primary information for the probes is shown in [Table 2](#t2-medscimonit-25-4423){ref-type="table"}. LDR was performed in a 10 μl reaction mixture containing 1×buffer, 1 μl of 2 pmol/μl each probe mix, 0.05 μl of 2 U of Taq DNA ligase (NEB Biotechnology, Shanghai, China), 4 μl ddH~2~O, and 4 μl multi-PCR product. The fluorescent products of LDR were distinguished by an ABI PRISM 377, and the results were analyzed with GeneMapper software (Applera Corporation, Norwalk, CT, USA). The quality of the genotype was controlled under blinded blood duplications.

Statistical analysis
--------------------

Clinical data were assessed using the *t*-test with SPSS Statistics software v. 17.0 (IBM Corporation, Armonk, NY, USA). The Hardy-Weinberg equilibrium (HWE) assumption was determined online using SHEsis Software (*<http://analysis.bio-x.cn>*) for each SNP in cases and controls separately. Allele frequencies were compared using chi-square analyses and Fisher's exact test (two-sided). SNP genotype frequencies and dominant/recessive model analysis of cases and controls were calculated by logistic regression analysis. *P* values \<0.05 were considered to be statistically significant. Haplotype analysis was conducted using SHEs is Software (*<http://analysis.bio-x.cn/SHEsisMain.htm>*) \[[@b21-medscimonit-25-4423],[@b22-medscimonit-25-4423]\]. Linkage disequilibrium analysis was examined using Haploview Software (*<http://www.broadinstitute.org/haploview/>*).

Results
=======

Clinical data analysis
----------------------

We identified significant differences in age, body mass index (BMI), sperm concentration, semen volume, seminal FSH, LH, T, fructose, α-glucosidase, zinc, and INHB between cases and controls (*P*\<0.05, [Table 3](#t3-medscimonit-25-4423){ref-type="table"}). There was no significant difference in semen pH or E~2~ between the 2 groups (*P*\>0.05, [Table 3](#t3-medscimonit-25-4423){ref-type="table"}).

Allele and genotype association analysis
----------------------------------------

We genotyped the *ACE* SNPs rs4316, rs4331, rs4343, and rs4362 in NOA cases and controls after removing failed genotype samples. Genotype and allele frequencies are summarized in [Table 4](#t4-medscimonit-25-4423){ref-type="table"}. All SNPs were in HWE (*P*=0.089 for rs4331, *P*=0.089 for rs4343, *P*=0.089 for rs4316, and *P*=0.381 for rs4362). However, our case-control analysis of SNP data showed no significant differences between cases and controls (*P*\>0.05). To further explore the genotypes of NOA-related SNPs, binary logistic regression analysis was used for dominance and recessive model analysis with SPSS v.17.0 software (IBM Corporation, Armonk, NY, USA), NOA pathogenicity as a dependent variable, and genetic model as an independent variable. [Table 4](#t4-medscimonit-25-4423){ref-type="table"} shows that there was no association between the 4 SNPs and cases and controls in recessive and dominant genetic models.

Haplotype analysis
------------------

Haploview software was used to analyze the haplotypes of the 4 *ACE* SNPs distributed on chromosome 17 ([Figure 1](#f1-medscimonit-25-4423){ref-type="fig"}). The SNPs formed a haplotype block with a coverage of 11 kb in the order *ACE* c.81C\>T (rs4316), *ACE* c.471A\>G (rs4331), *ACE* c.606G\>A (rs4343), and*ACE* c.1665T\>C (rs4362). Three haplotypes were identified in the block: TGAC, CAGT, and TGAT. A comparison of various haplotype frequencies in cases and controls is shown in [Table 5](#t5-medscimonit-25-4423){ref-type="table"}; no haplotype was significantly associated with NOA in the present study.

Discussion
==========

ACE was first identified as a key component of the RAS, and *ACE* on 17q23 encodes 2 isoforms in mammals. *sACE* is expressed widely in vascular endothelial cells, the kidney, and brain and is associated with blood pressure regulation \[[@b8-medscimonit-25-4423],[@b13-medscimonit-25-4423],[@b23-medscimonit-25-4423]\]. *sACE* is expressed in testicular Leydig cells, but not expressed in germinal cells \[[@b13-medscimonit-25-4423],[@b24-medscimonit-25-4423]\]. In contrast, tACE is specifically expressed in post-meiotic germinal cells during spermiogenesis and in mature spermatozoa \[[@b25-medscimonit-25-4423]\].

Although there is now a body of evidence implicating the RAS in pathophysiologies associated with reproductive function, the overall importance of the RAS in normal reproductive function is unclear \[[@b26-medscimonit-25-4423]\]. Previous studies using gene knock-out techniques showed that *tACE* played an important role in male fertility \[[@b15-medscimonit-25-4423]\]. Moreover, tACE from healthy functional spermatozoa was reported to have fertilizing ability \[[@b23-medscimonit-25-4423]\].

The role of ACE gene polymorphism in male infertility patients has been paid attention. A hypothesis has been proposed that SNP polymorphism can lead to changes in the expression of tACE gene, leading to fertilization failure \[[@b27-medscimonit-25-4423]\]. Novel tACE polymorphisms were identified in European-Americans and African-Americans \[[@b28-medscimonit-25-4423]\], while Kucera et al. \[[@b29-medscimonit-25-4423]\] detected different allele frequencies of ACE insertions/deletions in men with a pathological sperm count compared with men with normal fertility. Additionally, Li et al. \[[@b27-medscimonit-25-4423]\] reported that the ACE SNP rs4316 might be associated with infertility. However, Liao et al. \[[@b18-medscimonit-25-4423]\] found no significant difference in the frequency of 5 tACE SNPs between patients and controls from Singapore. In our study, 4 tACE SNPs were not found to be associated with NOA.

An interesting phenomenon is that ACE inhibitors improve sperm count and motility in a dose-dependent manner. Infertile males with poor semen quality can be improved by low-dose ACE inhibitors \[[@b30-medscimonit-25-4423]\]. However, it is not clear whether the effect of this inhibitor is related to changes in tACE activity. The change of ACE SNPs in male infertility is still controversial. Hence, these issues deserve further study in the future.

Conclusions
===========

The present study detected no significant differences in genotype and allele frequencies, or haplotype analysis of *ACE* SNPs rs4316, rs4331, rs4343, or rs4362 between NOA patients and healthy controls in a Chinese Han population from Northeast China. Together, these findings suggest the existence of ethnic differences in the distribution of SNPs, although larger collaborative studies involving other ethnicities are needed to confirm this.

**Source of support:** This work was supported by Clinical Medical Research Special Funds of Chinese Medical Association, P.R. China (17020200689)

**Conflict of interest**

None.

![Haplotype analysis of NOA-associated SNPs in chromosome 17. \[*ACE* c.81C\>T (rs4316), *ACE* c.471A\>G (rs4331), *ACE* c.606G\> A (rs4343), and *ACE* c.1665T\> C (rs4362)\]. Red squares indicate a complete chain.](medscimonit-25-4423-g001){#f1-medscimonit-25-4423}

###### 

Primers of target genes used in the PCR.

  Primer name   Sequence (5-3′)        PCR length              
  ------------- ---------------------- ----------------------- -----
  rs4331        TGCAGAACACCACTATCAAG   GAGCCACACACCTCCTCCA     96
  rs4343        GTGAGCTAAGGGCTGGA      CCAGCCCTCCCATGCCCATAA   109
  rs4316        TTCCTGCTGCTCTGCTACG    TGGGTGACTGTCACCTGTTG    74
  rs4362        GGAACTGGAACTGGATGATG   TGGGGCCCAGTGGCACAAG     100

###### 

Target gene probe sequences of LDR.

  Probe name      Sequence (5′-3′)                                                    LDR length
  --------------- ------------------------------------------------------------------- ------------
  rs4331_modify   P-GCTGCCCGTTCTAGGTCCTGTTTTTTTTTTTTTTTTTTTTT-FAM                     
  rs4331_A        TTTTTTTTTTTTTTTTTTCCTCCAGCTCCTGGGCAGGCAGT                           82
  rs4331_G        TTTTTTTTTTTTTTTTTTTTCCTCCAGCTCCTGGGCAGGCAGC                         84
  rs4343_modify   P-GTGGCCATCACATTCGTCAGTTTTTTTTTTTTTTTTTTTTTTTT-FAM                  
  rs4343_A        TTTTTTTTTTTTTTTTTTTTACAGGTCTTCATATTTCCGGGAT                         87
  rs4343_G        TTTTTTTTTTTTTTTTTTTTTTACAGGTCTTCATATTTCCGGGAC                       89
  rs4316_modify   P-GGGACCAGCAGAGGGTGCCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM         
  rs4316_C        TTTTTTTTTTTTTTTTTTTTTTTTTTCCTGTTGGGATGCCTCCTGGCTG                   102
  rs4316_T        TTTTTTTTTTTTTTTTTTTTTTTTTTTTCCTGTTGGGATGCCTCCTGGCTA                 104
  rs4362_modify   P-AAGTACCTGGAGCAGAGCGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM   
  rs4362_C        TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAACTGGATGATGAAGCTGACG               112
  rs4362_T        TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAACTGGATGATGAAGCTGACA             114

###### 

Clinical characteristics of control subjects and cases.

  Variables                        Patients (121)   Controls (256)   *P* value
  -------------------------------- ---------------- ---------------- -----------
  Age (years)                      30.00±5.69       25.35±5.51       \<0.001
  BMI (kg/m^2^)                    25.31±5.13       22.89±3.83       \<0.001
  pH                               7.48±0.41        7.51±0.06        0.314
  Sperm density (10^6^/mL)         0                66.88±11.11      \<0.001
  Sperm volume (mL)                2.74±1.49        3.69±1.29        \<0.001
  Fructose (μmol/eja)              66.47±57.96      20.40±12.88      \<0.001
  Alpha-glucosidase (mIU/eja)      41.25±43.95      30.32±18.99      0.004
  Seminal plasma zinc (μmol/eja)   7.45±5.31        2.91±2.88        \<0.001
  FSH (mIU/mL)                     19.42±11.62      3.35±1.58        \<0.001
  LH (mIU/mL)                      9.17±5.20        4.96±2.05        \<0.001
  PRL (μIU/mL)                     305.11±168.37    409.28±215.19    \<0.001
  E~2~ (pg/mL)                     35.46±25.32      34.21±11.85      0.520
  T (nmol/L)                       12.46±6.90       17.72±6.43       \<0.001
  INHB (pg/mL)                     51.90±84.52      200.93±71.27     \<0.001

*P*\<0.05 has statistical significance.

###### 

Genotypes and dominant/recessive model analysis of NOA-associated SNPs.

  dbsnp code   Cases (n=121)   Controls (n=256)   OR (95% CI)   *P* value                              
  ------------ --------------- ------------------ ------------- --------------- ---------------------- -----------------------------------------------------------
  **rs4331**                                                                                           
   A A         14              \(153\) 63.20      42            \(321\) 62.70   0.978 (0.712\~1.342)   0.889
   A G         61              107                                                                     
   G G         46              107                                                                     
   A\>G        60 (24.80)                         149 (29.10)                   0.799 (0.489\~1.239)   0.123[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   GG+AG/AA    107/14                             214/42                        0.987 (0.956\~1.019)   0.417[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   GG/AG+AA    46/75                              107/149                       /                      /
  **rs4343**                                                                                           
   A A         46              \(153\) 63.20      107           \(321\) 62.70   1.022 (0.745\~1.404)   0.889
   A G         61              107                                                                     
   G G         14              42                                                                      
   G\>A        60 (24.80)                         149 (29.10)                   0.799 (0.489\~1.239)   0.123[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   AA+AG/GG    107/14                             214/42                        0.987 (0.956\~1.019)   0.417[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   AA/AG+GG    46/75                              107/149                       /                      /
  **rs4316**                                                                                           
   C C         14              \(153\) 63.20      42            \(321\) 62.70   0.978 (0.712\~1.342)   0.889
   C T         61              107                                                                     
   T T         46              107                                                                     
   C\>T        60 (24.80)                         149 (29.10)                   0.799 (0.489\~1.239)   0.123[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   TT+CT/CC    107/14                             214/42                        0.987 (0.956\~1.019)   0.417[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   TT/CT+CC    46/75                              107/149                       /                      /
  **rs4362**                                                                                           
   C C         40              \(143\) 59.10      96            \(308\) 60.20   0.957 (0.700\~1.306)   0.780
   C T         63              116                                                                     
   T T         18              44                                                                      
   T\>C        58 (23.97)                         140 (27.34)                   1.303 (0.807\~2.106)   0.179[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   CC+CT/TT    103/18                             212/44                        0.986 (0.953\~1.020)   0.408[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}
   CC/CT+TT    40/81                              96/160                        0.090 (0.000\~)        0.415[\*](#tfn2-medscimonit-25-4423){ref-type="table-fn"}

Binary logistic regression analysis;

*P*\<0.05 has statistical significance.

###### 

Haplotype analysis of NOA-associated SNPs (rs4316, rs4331, rs4343, rs4362).

  Haplotype   Cases frequency(%)   Controls frequency(%)   P value
  ----------- -------------------- ----------------------- ---------
  TGAC        59.1                 59.8                    0.860
  CAGT        36.8                 36.9                    0.971
  TGAT        4.1                  2.9                     0.389

*P*\<0.05 has statistical significance.
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